Treatment with oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule improves hereditary angioedema attack symptoms

John Anderson¹, Joshua S. Jacobs², H. Henry Li³, Michael E. Manning⁴, Emel Aygören-Pürsün⁵, Maria Luisa Baeza⁶, Laurence Bouillet⁷, Hugo Chapdelaine⁸, Danny M. Cohn⁹, Aurélie Du-Thanh¹⁰, Olivier Fain¹¹, Henriette Farkas¹², Jens Greve¹³, Mar Guilarte¹⁴, David Hagin¹⁵, Roman Hakl¹⁶, Aharon Kessel¹⁷, Sorena Kiani-Alikhan¹⁸, Pavlina Králícková¹⁹, Ramon Lleonart²⁰, Markus Magerl²¹, Avner Reshef²², Bruce Ritchie²³, Giuseppe Spadaro²⁴, Maria Staevska²⁵, Petra Staubach²⁶, Marcin Stobiecki²⁷, Gordon L. Sussman²⁸, Milliam H. Yang³⁰, Marie-Helene Jouvin³¹, Rafael Crabbé³², Simone van Leeuwen³³, Huaihou Chen³¹, Li Zhu³⁴, Jochen Knolle³⁵, Anne Lesage³⁶, Peng Lu³⁴, Marcus Maurer²¹, Marc A. Riedl³⁷

¹Birmingham, AL, United States of America; ³Chevy Chase, MD, United States of America; ⁴Scottsdale, AZ, United States of America; ³Chevy Chase, MD, United States of America; ⁴Scottsdale, AZ, United States of America; ¹Paris, France; Hungary; ¹³Ulm, Germany; ¹⁴Barcelona, Spain; ¹⁵Tel Aviv, Israel; ¹⁶Brno, Czech Republic; ¹⁶Brno, Czech Republic; ¹⁷Haifa, Israel; ¹⁸London, United Kingdom; ¹⁹Hradec Kralove, Czech Republic; ¹⁷Haifa, Israel; ¹⁸London, United Kingdom; ¹⁹Hradec Kralove, Czech Republic; ²⁰Barcelona, Spain; ²¹Rerlin, Germany; ²²Ashkelon, Israel; ¹⁸London, United Kingdom; ¹⁹Hradec Kralove, Czech Republic; ¹⁷Haifa, Israel; ¹⁸London, United Kingdom; ¹⁹Hradec Kralove, Czech Republic; ¹⁸London, United Kingdom; ¹⁹Hradec Kralove, Czech Republic; ¹⁸London, United Kingdom; ¹⁹Hradec Kralove, Poland; ¹⁸London, United Kingdom; ¹⁹Hradec Kralove, Czech Republic; ¹⁸London, United Kingdom; ¹⁹Hradec Kralove, Poland; ¹⁸London, United Kingdom; ¹⁹Hradec Kralove, Czech Republic; ¹⁸London, United Kingdom; ¹⁹Hradec Kralove, Poland; ¹⁰Hradec Kralove, ¹⁰Hradec Kralov ²⁸Toronto, ON, Canada; ²⁹Brighton, United States of America; ³⁵Frankfurt, Germany; ³⁶Schilde, Belgium; ³⁷La Jolla, CA, United States of America (former Pharvaris employees); ³²Bassins, Switzerland; ³⁴Lexington, MA, United States of America; ³⁵Frankfurt, Germany; ³⁶Schilde, Belgium; ³⁷La Jolla, CA, United States of America

Introduction

- Approved therapies for hereditary angioedema (HAE) attacks are administered parenterally with substantial treatment burden due to administration time and risk of pain or other injection site reactions¹⁻⁴, with treatment of many attacks being delayed or forgone.⁵⁻⁶
- An unmet need exists for on-demand oral therapies that are effective and well-tolerated and may reduce the treatment burden enabling prompt administration as recommended by international clinical guidelines.⁷⁻⁹
- Deucrictibant immediate-release (IR) capsule (PHVS416) is an investigational formulation containing deucrictibant (PHA121), a highly potent, specific, and orally bioavailable competitive antagonist of the bradykinin B2 receptor.¹⁰⁻¹¹
- In the Phase 2 RAPIDe-1 trial (NCT04618211¹²) deucrictibant IR capsule reduced time to onset of symptom relief and to attack resolution measured through the visual analogue scale-3 (VAS-3) and substantially reduced use of rescue medication.¹³⁻¹⁴

Methods

- RAPIDe-1 was a Phase 2, double-blind, placebo-controlled, randomized, crossover, doseranging trial of deucrictibant IR capsule for the acute treatment of angioedema attacks in patients with HAE-1/2.
- A primary analysis was performed including 147 qualifying HAE attacks treated by 62 participants with double-blinded placebo or deucrictibant IR capsule 10, 20, or 30 mg (modified intent-to-treat analysis, mITT = all randomized participants with ≥ 1 treated HAE attack and VAS results at both pre-treatment and ≥ 1 post-treatment time point).
- Mean Symptom Complex Severity (MSCS) score and Treatment Outcome Score (TOS) are validated composite scores based on patient-reported symptoms of attacks at the affected body sites, included in ecallantide clinical trials¹⁵⁻¹⁷. Changes in MSCS score and in TOS from pre-treatment to 4 hours post-treatment were secondary endpoints of RAPIDe-1.
- MSCS is a point-in-time measure of symptom severity:
- Patient-rated severity of each affected symptom on a categorical scale (0 = normal, 1 = mild, 2 = moderate, 3 = severe)
- Calculated as average score from all affected body sites (symptom complexes)
- Decrease in score reflects improvement in symptom severity
- TOS is a measure of symptom response to treatment:
- Patient assessment of response for each affected body site on categorical scale (significant improvement [100], improvement [50], same [0], worsening [-50], significant worsening [-100])
- Calculated as weighted average of the response at all body sites using pre-treatment severity as weight
- Increase in score reflects improvement in symptom from pre-treatment
- Complex Assessment questions evaluate patient-reported change in attack symptoms from pre-treatment
- (a lot better or resolved a little better same a little worse a lot worse)






Figure 1. RAPIDe-1 trial design schematic










Figure 3. TOS measured up to 4 h post-treatment

_research grant support, consultancy fees, and/or clinical trial fees - J.A.: BioCryst, BioRarin, CSL Behring, Cycle Pharmaceuticals, Pharming, Pharvaris, Takeda. H.H.L.: BioCryst, BioRarin, CSL Behring, Cycle, Genentech, GSK, KalVista, Pharming, Pharvaris, Takeda. H.H.L.: BioCryst, BioRarin, CSL Behring, Cycle pharmaceuticals, Pharming, Pharvaris, Takeda. H.H.L.: BioCryst, BioRarin, CSL Behring, Cycle Pharmaceuticals, Pharming, Pharvaris, Takeda. M.E.M.: Allakos, Amgen, AstraZeneca, BioCryst, BioRarin, CSL Behring, Cycle pharmaceuticals, Pharming, Pharvaris, Takeda. H.H.L.: BioCryst, BioRarin, CSL Behring, Cycle, Behring, Cycle, Behring, Cycle pharmaceuticals, Pharming, Pharvaris, Takeda. H.H.L.: BioCryst, BioRarin, CSL Behring, Pharvaris, Takeda. H.H.L.: BioCryst, BioRarin, CSL Behring, Cycle pharmaceuticals, Pharming, Pharvaris, Takeda. H.E.B.: BioCryst, BioRarin, CSL Behring, Cycle pharmaceuticals, Pharming, Pharvaris, Takeda. H.E.B.: BioCryst, BioRarin, CSL Behring, Cycle, Behring, Cycle pharmaceuticals, Pharming, Pharvaris, Takeda. H.H.L.: BioCryst, BioRarin, CSL Behring, Cycle pharmaceuticals, CSL Behring, Cycle pharmaceuticals, Pharming, Pharvaris, Takeda. H.E.B.: BioCryst, BioRarin, CSL Behring, Cycle pharmaceuticals, CSL Behri _Exer is bire/Takeda. D.H.: BioCryst, CSL Behring, Pharvaris, Shire/Takeda. D.H.: BioCryst, CSL Behring, Pharvaris, Shire/Takeda. D.H.: BioCryst, CSL Behring, Pharvaris, Takeda. D.H.: BioCryst, CSL Behring, Pharvaris, Takeda. D.H.: BioCryst, CSL Behring, Novartis, Shire/Takeda. A.K.: CSL Behring, Pharvaris, Shire/Takeda. D.H.: BioCryst, CSL Behring, Pharvaris, Shire/Takeda. D.H.: BioCryst, CSL Behring, Pharvaris, Shire/Takeda. D.H.: BioCryst, CSL Behring, Novartis, Takeda. D.B.: CSL Behring, Pharvaris, Takeda. D.H.: BioCryst, CSL Behring, Pharvaris, Shire/Takeda. D.H.: BioCryst, CSL _restrictures and consultant to Pharvaris. B.V.L.: employee of SLC Consultants, holds stocks in Pharvaris, holds stocks in Pharvari options in Pharvaris. A.L.: employee of GravMatters Consulting, Pharvaris, RegenexBio, Sanofi-Regeneron, Takeda

Number of patients with post-treatment TOS PRO Number of attacks with post-treatment TOS PRO Attacks with onset of all symptor "a little better" within 48 hours -Median (95% CI) time (hours) to onset of symptom relief by KM e

Number of patients with post-treatment TOS PRO Number of attacks with post-treatment TOS PRO Attacks with onset of all sympto "a lot better or resolved" within Median (95% CI) time (hours) to or complete symptom relief by Kl

Almost complete or complete symptom relief = The time point when TOS PRO first reaches "A lot better or resolved" for all symptom complexes affected at baseline, and no new symptom in any other symptom complex is reported.

Table 2. Time to almost complete or complete symptom relief measured through TOS

Conclusions

- treatment with deucrictibant IR capsule
- https://ir.Pharvaris.com/.

References

¹Berinert[®] [package insert], https://labeling.cslbehring.com/pi/us/berinert/en/berinert-prescribing-information.pdf (accessed 18 July 2023) ²Firazyr[®] [package insert], https://www.shirecontent.com/PI/PDFs/Firazyr_USA_ENG.pdf (accessed 18 July 2023). ³Kalbitor[®] [package insert] https://www.shirecontent.com/PI/PDFs/Kalbitor_USA_ENG.pdf (accessed 18 July 2023). ⁴Ruconest[®] [package insert] https://www.ruconest.com/wp-content/uploads/Ruconest_PI_Apr2020.pdf (accessed 18 July 2023). ⁵Tuong LA et al. Allergy Asthma Proc 2014;35:250-4. 6US Food and Drug Administration, Center for Biologics Evaluation and Research. The voice of the patient – Hereditary angioedema May, 2018. https://www.fda.gov/media/113509/download (accessed 18 July 2023). ⁷Betschel S et al. Allergy Asthma Clin Immunol 2019;15:72. ⁸Busse PJ et al. J Allergy Clin Immunol Pract 2021 2021;9:132-50. ⁹Maurer M et al. Allergy 2022;77:1961-90. ¹⁰Lesage A et al. Front Pharmacol 2020;11:916. ¹¹Lesage A et al. Int Immunopharmacol 2022;105:108523. ¹²https://clinicaltrials.gov/ct2/show/NCT04618211 (accessed 18 July 2023). ¹³Maurer M et al. AAAAI 2023;411; ¹⁴Farkas H et al. 13th C1-inhibitor Deficiency and Angioedema Workshop 2023;0-19. ¹⁵Vernon MK et al Qual Life Res 2009;18:929-39. ¹⁶Cicardi M et al. N Engl J Med 2010:363:523-31. ¹⁷Levy RJ et al. Ann Allergy Asthma Immunol 2010;104:523-9.

	Placebo	Deucrictibant IR capsule 10 mg	Deucrictibant IR capsule 20 mg	Deucrictibant IR capsule 30 mg
	49	21	16	19
	49	36	28	29
om complexes – n (%)	18 (36.7%)	32 (88.9%)	25 (89.3%)	27 (93.1%)
estimate	7.62 (3.95, -)	1.89 (0.97, 3.97)	2.15 (1.75, 4.00)	1.98 (1.80, 3.87)

Onset of symptom relief = The time point when TOS PRO first reaches at least "A little better" for all symptom complexes affected at baseline, and no new symptom in any other symptom complex is reported. Relief is confirmed if the improvement is sustained at 2 consecutive time points.

Table 1. Time to onset of symptom relief measured through TOS

	Placebo	Deucrictibant IR capsule 10 mg	Deucrictibant IR capsule 20 mg	Deucrictibant IR capsule 30 mg
	49	21	16	19
	49	36	28	29
om complexes 48 hours – n (%)	13 (26.5%)	30 (83.3%)	23 (82.1%)	25 (86.2%)
o almost complete KM estimate	23.28 (5.78, 47.17)	4.02 (3.93, 5.77)	5.93 (3.90, 8.58)	4.12 (3.92, 7.22)

• In the Phase 2 RAPIDe-1 trial deucrictibant IR capsule improved symptoms and reduced time to symptom relief and to resolution of HAE attacks

• Clinical meaningful improvement of symptoms was observed during the first hours after

• The U.S. FDA has placed a hold on clinical trials of deucrictibant for long-term prophylaxis in the United States of America. For the latest information and updates visit: